EndGenitor Technologies, Inc.’s strategy is to rapidly commercialize adult stem cell products for sale to researchers in industry and academia. As it grows its market presence and diversifies its product lines, EndGenitor expects to launch proprietary novel stem cell therapeutics for the treatment of debilitating chronic degenerative diseases. The company is solely focusing on commercializing cell products from adult tissues that are free from any ethical controversy.
EndGenitor has licensed (from Indiana University Research & Technology Corporation) technology relating to proprietary, novel, and highly proliferative stem cell populations that mature into the lining of new blood vessels. This technology is patent pending. EndGenitor scientists are also engaged in exciting research which could lead to novel methods for stimulating and promoting blood vessel formation and growth.
EndGenitor's stem cell products are purchased by clients in the research community through the company’s partnership with a national tissue collection/distribution agency located in Philadelphia, the National Disease Research Interchange (NDRI). Research products for EndGenitor Technologies, Inc.® include:
- Human umbilical cord blood CD34+ enriched hematopoietic stem cells (HSCs)
- Human umbilical cord blood CD31+;CD45- cloned endothelial colony-forming cells (ECFCs™)
- Human umbilical cord blood CD34+;CD38- enriched hematopoietic stem cells (HSCs)
EndGenitor also partners in collaborative research with its founding scientists at the Indiana University School of Medicine (Drs. Mervin Yoder and David Ingram) to generate additional products.
Phone:
(317) 278-1523
E-mail:
info@endgenitor.com
Mail:
351 W. 10th St., Suite 223
Indianapolis, IN 46202-4125
Fax:
(317) 278-1522
